Biodexa Pharma - רווח נקי למניה (EPS TTM) BDRX

The biopharmaceutical sector of Biodexa Pharmaceuticals (BDRX) is subject to geopolitical risks and logistics disruptions. Proprietary targeted drug delivery methods to tumors guarantee business stability. Changes in the rolling annual EPS demonstrate profitability, where the -53.68 metric reflects current dynamics. The company is currently actively researching orphan drugs for the therapy of aggressive brain neoplasms amidst a shortage of funds.

Net income per share over twelve months measures the portion of equity attributable to a single security after all expenses are deducted. This metric allows an investor to assess the actual efficiency of cash flow generation. By analyzing the annual net income per share chart, one can determine the stability of the business. For Biodexa Pharmaceuticals (BDRX), this indicator reflects the profitability of complex oncology drug distribution systems. Optimizing logistics to clinics directly impacts the final financial result.